Results 11 to 20 of about 216,825 (268)

Baroreflex activation therapy in advanced heart failure therapy: insights from a real‐world scenario

ESC Heart Failure, 2023
Aims Baroreflex activation therapy (BAT) is an innovative treatment option for advanced heart failure (HFrEF). We analysed patients' BAT acceptance and the outcome of BAT patients compared with HFrEF patients solely treated with a guideline‐directed ...
Denise Guckel, Thomas Eitz, Mustapha El Hamriti, Martin Braun, Moneeb Khalaph, Guram Imnadze, Thomas Fink, Vanessa Sciacca, Christian Sohns, Philipp Sommer, Georg Nölker   +10 more
doaj   +1 more source

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

Frontiers in Pharmacology, 2021
Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1)
Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng   +7 more
doaj   +1 more source

Development of advanced inductive scenarios for ITER [PDF]

Nuclear Fusion, 2013
Since its inception in 2002, the International Tokamak Physics Activity topical group on Integrated Operational Scenarios (IOS) has coordinated experimental and modelling activity on the development of advanced inductive scenarios for applications in the ITER tokamak.
Luce, T. C., Challis, C. D., Ide, S., Joffrin, E., Kamada, Y., Politzer, P. A., Schweinzer, J., Sips, A. C. C., Stober, J., Giruzzi, G., Kessel, C. E., Murakami, M., Na, Y. S., Park, J. M., Polevoi, A. R., Budny, R. V., Citrin, J., Garcia, J., Hayashi, N., Hobirk, J., Hudson, B. F., Imbeaux, F., Isayama, A., Mcdonald, D. C., Nakano, T., Oyama, N., Parail, V. V., Petrie, T. W., Petty, C. C., Suzuki, T., Wade, M. R., Abel, I., Afanesyev, V., Aftanas, M., Agarici, G., Aggarwal, K. M., Aho Mantila, L., Ahonen, E., Aints, M., Airila, M., Akers, R., Alarcon, T., Albanese, R., Alexeev, A., Alfier, A., Allan, P., Almaviva, S., Alonso, A., Alper, B., Altmann, H., Alves, D., Ambrosino, G., Amosov, V., Andersson, F., Anderssonsund ́en, E., Andreev, V., Andrew, Y., Angelone, M., Anghel, M., Anghel, A., Angioni, C., Apruzzese, G., Arcis, N., Arena, P., Argouarch, A., Ariola, M., Armitano, A., Armstrong, R., Arnoux, G., Arshad, S., Artaserse, G., Artaud, J. F., Ash, A., Asp, E., Asunta, O., Atanasiu, C. V., Atkins, G., Avotina, L., Axton, M. D., Ayres, C., Baciero, A., Bailescu, V., Baiocchi, B., Baker, R. A., Balboa, I., Balden, M., Balorin N. Balshaw, C. Balorin N. Balshaw, Banks, J. W., Baranov, Y. F., Barbier, D., Barlow, I. L., Barnard, M. A., Barnsley, R., Barrena, L., Barrera, L., Baruzzo, M., Basiuk, V., Bateman, G., Batistoni, P., Baumgarten, N., Baylor, L., Bazylev, B., Beaumont, P. S., Beausang, K., B ́ecoulet, M., Bekris, N., Beldishevski, M., Bell, A. C., Belli, F., Bellinger, M., Bellizio, T., Belo, P. S. A., Belonohy, E., Bennett, P. E., Benterman, N. A., Berger By, G., Bergsåker, H., Berk, H., Bernardo, J., Bernert, M., Bertrand, B., Beurskens, M. N. A., Bieg, B., Bienkowska, B., Biewer, T. M., Bigi, M., B ́ılkov ́a, P., Bin, W., Bird, J., Bizarro, J., Bj ̈orkas, C., Blackman, T. R., Blanchard, P., Blanco, E., Blum, J., Bobkov, V., Boboc, A., Boilson, D., Bolshakova, I., Bolzonella, T., Boncagni, L., Bonheure, G., Bonnin, X., Borba, D., Borthwick, A., Botrugno, A., Boulbe, C., Bouquey, F., Bourdelle, C., Bovert, K. V., Bowden, M., Boyce, T., Boyer, H. J., Bozhenkov, A., Brade, R. J., Bradshaw, J. M. A., Braet, J., Braic, V., Braithwaite, G. C., Brault, C., Breizman, B., Bremond, S., Brennan, P. D., Brett, A., Breue, J., Brezinsek, S., Bright, M. D. J., Briscoe, F., Brix, M., Brombin, M., Brown, B. C., Brown, D. P. D., Brzozowski, J., Bucalossi, J., Buckley, M. A., Budd, T., Bunting, P., Buratti, P., Burcea, G., Burckhart, A., Butcher, P. R., Buttery, R. J., Cahyna, P., Calabr`o, G., Callaghan, C. P., Caminade, J. P., Camp, P. G., Campling, D. C., Caniello, R., Canik, J., Cannas, B., Capel, A. J., Carannante, G., Card, P. J., Cardinali, A., Carlstrom, T., Carman, P., Carralero, D., Carraro, L., Carter, T., Luce, T., Romanelli, F.   +201 more
openaire   +4 more sources

Patient preferences for advanced therapies in ulcerative colitis using conjoint analysis [PDF]

Intestinal Research
Background/Aims Selecting an optimal advanced therapy for ulcerative colitis (UC) is difficult because of the increasing number of available therapies. This study assessed UC patients’ preferences for drug profiles in decision-making regarding advanced ...
Taku Kobayashi, Naomi Mizuno, Noriko Sato, Yutaka Kawaguchi, Yoshiko Ikawa, Naruyasu Komorita, Hirono Ishikawa   +6 more
doaj   +1 more source

Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario

Journal of Market Access & Health Policy, 2022
Background Precision oncology has a prominent role in nonsquamous non-small cell lung cancer (nsNSCLC) treatment progress; however, its access in a real-world scenario might be limited.Objective To investigate the time spent in nsNSCLC molecular profile ...
Flavia A. Duarte, Carlos Gil Ferreira, Rodrigo Dienstmann, Bruno L. Ferrari, Matheus Costa E Silva, Pedro Nazareth A. Junior, Paulo Guilherme de O. Salles, Paulo Henrique C. Diniz   +7 more
doaj   +1 more source

Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer

Cancer Medicine, 2022
This review focuses on patients with differentiated thyroid carcinoma (DTC) associated with multiple primary malignant neoplasm (MPMN) treated by multikinase inhibitors (MKIs) as systemic treatment for advanced disease.
Marcel Sambo
doaj   +1 more source

Advanced Nuclear Energy Development Scenario Study

Yuanzineng kexue jishu
Nuclear energy is a safe, economical and efficient clean low-carbon energy resource. Its safety and large-scale development of nuclear energy are of great significance for optimizing the energy structure and promoting green and low-carbon development ...
YANG Yong, ZHOU Peide, YE Guoan, YANG Hongyi, HU Yun, SONG Yingyun
doaj   +1 more source

Adaptive Handover Decision Algorithm Based on Multi-Influence Factors through Carrier Aggregation Implementation in LTE-Advanced System

Journal of Computer Networks and Communications, 2014
Although Long Term Evolution Advanced (LTE-Advanced) system has benefited from Carrier Aggregation (CA) technology, the advent of CA technology has increased handover scenario probability through user mobility.
Ibraheem Shayea, Mahamod Ismail, Rosdiadee Nordin, Hafizal Mohamad   +3 more
doaj   +1 more source

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

Therapeutic Advances in Medical Oncology, 2021
The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise ...
Ramez N. Eskander, Matthew A. Powell
doaj   +1 more source

Multicell cooperation for LTE-advanced heterogeneous network scenarios

IEEE Wireless Communications, 2013
In this article we present two promising practical use cases for simple multicell cooperation for LTE-Advanced heterogeneous network scenarios with macro and small cells. For co-channel deployment cases, we recommend the use of enhanced interference coordination, or eICIC, to mitigate cross-tier interference and ensure sufficient offload of users from ...
Beatriz Soret, Hua Wang, Klaus I. Pedersen, Claudio Rosa   +3 more
openaire   +3 more sources